UPC rejects Alexion’s rehearing bid in spat with Amgen and Samsung

Court sets strict rules on rehearing's, saying "only fundamental procedural defects can be the basis for a rehearing” | Follows UK blow to Alexion, allowing biosimilars onto market.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

Chinese medtech company fined by UPC over injunction breaches

21 May 2026 The court has imposed a financial penalty after finding it continued promoting banned devices online despite an injunction covering five European countries.

Europe

Orrick lands five-member M&A team in Paris

18 May 2026 A high-profile Paris-based partner and four others join the firm, bringing experience across M&A, venture capital and life sciences-focused transactions.

Europe

IP in the deal room: The risks that bite before, during and after closing

7 May 2026 Experts from Johnson & Johnson and Novartis took the stage at INTA to share the pitfalls lurking inside mergers, acquisitions and spin-offs and what in-house counsel can do about them.

More features

Battle over inhaler shape ends badly for Boehringer

Chinese medtech company fined by UPC over injunction breaches

Healthcare leads sweeping AI partnership in Singapore

Jones Day adds in-house biologics specialist to Boston office

Kirkland & Ellis subject of alleged conflict in trade secrets clash

Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme

Orrick lands five-member M&A team in Paris

AbbVie’s trade secret suit against a Chinese rival gets green light

UPC rejects Alexion’s rehearing bid in spat with Amgen and Samsung

More on this story

Editor's picks

Editor's picks

More features